SODIUM SUCCINATE
Clinical safety rating
cautionComprehensive clinical and safety monograph for SODIUM SUCCINATE (SODIUM SUCCINATE).
Sodium succinate is a salt of succinic acid, which serves as an intermediate in the tricarboxylic acid (TCA) cycle. It acts as a metabolic supplement, enhancing cellular respiration and energy production by providing substrate for the TCA cycle. It also exhibits antioxidant properties by scavenging free radicals.
| Metabolism | Sodium succinate is metabolized via the tricarboxylic acid (TCA) cycle to carbon dioxide and water, with energy release. No specific cytochrome P450 enzymes are involved. |
| Excretion | Renal excretion of unchanged drug; less than 5% biliary/fecal. |
| Half-life | 5-10 minutes; rapid elimination limits systemic effects. |
| Protein binding | Not significantly protein bound (<5%). |
| Volume of Distribution | 0.3-0.5 L/kg; limited to extracellular fluid. |
| Bioavailability | Not applicable; administered intravenously; no oral bioavailability due to rapid metabolism. |
| Onset of Action | Intravenous: within 30 seconds to 1 minute. |
| Duration of Action | 5-10 minutes; brief duration due to rapid metabolism and excretion. |
| Molecular Weight | 140.09 |
No established standard dosing for sodium succinate as a therapeutic agent; it is used as a pharmaceutical excipient or buffering agent in intravenous formulations. For buffering purposes, typical concentrations range from 0.5% to 2% in injection solutions, administered intravenously at rates adjusted per clinical need.
| Dosage form | INJECTABLE |
| Renal impairment | No renal dose adjustment data available; sodium succinate is not renally excreted in significant amounts and is unlikely to accumulate in renal impairment, but caution with sodium load in severe renal dysfunction. |
| Liver impairment | No hepatic dose adjustment data available; no expected impact of hepatic impairment on sodium succinate disposition. |
| Pediatric use | No established pediatric dosing; use as excipient follows adult concentration guidelines with weight-based fluid calculations. |
| Geriatric use | No specific geriatric dose adjustment; consider sodium load and renal function in elderly patients with comorbidities. |
| 1st trimester | No adequate data on use in first trimester; animal studies show no evidence of harm at therapeutic doses, but risk cannot be excluded. |
| 2nd trimester | No evidence of fetal risk in animal studies during organogenesis; limited human data suggest safety, but use only if clearly needed. |
| 3rd trimester | No known adverse fetal effects in third trimester; however, use with caution as succinate may affect maternal acid-base balance. |
Clinical note
Comprehensive clinical and safety monograph for SODIUM SUCCINATE (SODIUM SUCCINATE).
| Placental transfer | Likely crosses placenta due to low molecular weight; no specific studies available, but theoretical risk of transfer based on physicochemical properties. |
| Breastfeeding | Excretion into breast milk is unknown; due to low molecular weight, may be present. Use with caution, monitor infant for potential gastrointestinal effects. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | No human or animal data available; sodium succinate is a Krebs cycle intermediate with essential metabolic roles; theoretical fetal risk is low, but administration during pregnancy should be cautious and only if clearly needed. |
| Fetal Monitoring | No specific monitoring requirements; standard maternal vital signs and fetal heart rate monitoring during administration if used in obstetric emergencies. |
| Fertility Effects | No known effects on fertility; not studied. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to sodium succinate or any excipientSevere renal impairment (eGFR <30 mL/min/1.73m²) due to risk of sodium overload
| Precautions | Use with caution in patients with renal impairment due to sodium content; monitor serum sodium levels. May cause transient hypotension or hypertension. Avoid rapid intravenous administration to prevent adverse cardiac events. |
| Food/Dietary | No known food interactions. |
| Clinical Pearls | Sodium succinate is used as a component of succinylated gelatin solutions for volume expansion. Monitor for hypernatremia and metabolic alkalosis due to succinate metabolism. Avoid in patients with severe renal impairment. |
| Patient Advice | This medication is given by healthcare professionals; no self-administration. · Report any signs of allergic reaction, such as rash or difficulty breathing. · Inform your doctor if you have kidney problems or a history of high sodium levels. |
Loading safety data…